By comparing the mutation among the two genes and prognostic indicators (Table 3), the MM group (i.e., mutant in MYD88 and TP53) was presented with the worst prognosis in terms of ECOG score (P<0.001) and cancer stage (P=0.04). This evidence concerns the gene MYD88 and Miyoshi myopathy.